Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PTEN inact mut XL147 prostate adenocarcinoma sensitive detail...
PTEN inact mut Paclitaxel + XL147 prostate adenocarcinoma sensitive detail...
ATM L1449* Olaparib prostate adenocarcinoma predicted - sensitive detail...
BRAF K601E Trametinib prostate adenocarcinoma no benefit detail...
MLH1 negative Pembrolizumab prostate adenocarcinoma sensitive detail...
MSH6 negative Pembrolizumab prostate adenocarcinoma sensitive detail...
RB1 del Decitabine prostate adenocarcinoma sensitive detail...
FGFR2 amp Tinengotinib prostate adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00002651 Phase III Bicalutamide Goserelin Hormone Therapy in Treating Men With Stage IV Prostate Cancer Completed CAN 0
NCT00223665 Phase II Leuprolide Flutamide Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy Completed USA 0
NCT00268476 Phase II Abiraterone + Prednisolone Metformin Abiraterone + Enzalutamide + Prednisolone Celecoxib Estradiol Zoledronic acid Docetaxel + Prednisolone Docetaxel + Prednisolone + Zoledronic acid Celecoxib + Zoledronic acid Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) Active, not recruiting GBR 1
NCT00303784 Phase III Estradiol Goserelin Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) Unknown status GBR 0
NCT00536991 Phase Ib/II Prednisone Calcitriol Ketoconazole Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer Terminated USA 0
NCT00541047 Phase III Leuprolide Goserelin Bicalutamide Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) Completed GBR | CAN 0
NCT00589420 Phase II Docetaxel + Sorafenib Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy Completed USA 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00859781 Phase II Prednisone Ketoconazole 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Active, not recruiting USA 0
NCT00936390 Phase III Flutamide Goserelin Leuprolide Triptorelin Bicalutamide Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Active, not recruiting USA | CAN 0
NCT01174199 Phase I Temsirolimus + Vorinostat Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer Terminated USA 0
NCT01313559 Phase II Everolimus + Pasireotide Pasireotide Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer Terminated USA 0
NCT01342367 Phase I Bicalutamide Dutasteride Finasteride Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer Active, not recruiting USA 0
NCT01409200 Phase II Axitinib Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis Active, not recruiting USA 0
NCT01420250 Phase I Bicalutamide Cabazitaxel Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer Completed USA 0
NCT01485861 Phase II Apitolisib Abiraterone Ipatasertib Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy Completed USA | NLD | ITA | GBR | FRA | ESP 3
NCT01498978 Phase II Ipilimumab Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Completed USA 0
NCT01503229 Phase II Prednisone Abiraterone Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Completed USA 0
NCT01513733 Phase I Tasquinimod Cabazitaxel The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer Completed USA 0
NCT01548807 Phase I Everolimus Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy Completed USA 0
NCT01560923 Phase II Sipuleucel-T Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Completed USA 0
NCT01619813 Phase II Docetaxel + Prednisone Pelareorep Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer Completed CAN 0
NCT01630590 Phase II Cabozantinib Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer Completed USA 0
NCT01681433 Phase II Prednisone Abiraterone Apatorsen OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone Terminated USA | CAN 0
NCT01688492 Phase Ib/II Abiraterone + Prednisone Ipilimumab Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA 0
NCT01695473 Phase II Buparlisib Neoadjuvant BKM120 in High-risk Prostate Cancer Terminated USA 0
NCT01703065 Phase I Cabozantinib Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer Terminated USA 0
NCT01706458 Phase II pTVG-HP plasmid DNA vaccine Sipuleucel-T Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer Completed USA 0
NCT01709734 Phase II Galeterone A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Terminated USA | CAN 0
NCT01786265 Phase II Goserelin Degarelix Abiraterone Prednisone Leuprolide Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone Active, not recruiting USA 0
NCT01787331 Phase II Itraconazole A Phase II Study of Itraconazole in Biochemical Relapse Completed USA 0
NCT01790126 Phase II Apalutamide The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer Completed USA 0
NCT01804465 Phase II Ipilimumab A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer Completed USA 0
NCT01807065 Phase II Sipuleucel-T Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Completed USA 0
NCT01812668 Phase I Cabozantinib Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Completed USA 0
NCT01832259 Phase II Pazopanib A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection Completed USA 0
NCT01845792 Phase II Cabazitaxel Abiraterone Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer Terminated USA 0
NCT01848067 Phase Ib/II Abiraterone Prednisone Alisertib Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Completed USA 0
NCT01885949 Phase II Enzalutamide + Tivozanib Tivozanib + Enzalutamide in Adv Prostate Cancer Active, not recruiting USA 0
NCT01927627 Phase II Enzalutamide Enzalutamide in Patients With High-risk Prostate Cancer Completed USA 0
NCT01940276 Phase II Abiraterone + Prednisone Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer Completed USA 0
NCT01942837 Phase II Enzalutamide Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling Completed USA 0
NCT01946204 Phase III Apalutamide A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) Active, not recruiting USA | NZL | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT01949337 Phase III Abiraterone Prednisone Enzalutamide Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Active, not recruiting USA | CAN 1
NCT01961843 Phase I Prednisone Abiraterone Abiraterone Acetate for Castrate Resistant Prostate Cancer Active, not recruiting USA 0
NCT01977651 FDA approved Enzalutamide A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide Completed USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT01996696 Phase II Metformin A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer. Terminated CAN 0
NCT02003924 Phase III Enzalutamide Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT02023463 Phase I Goserelin Enzalutamide Leuprolide Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer Active, not recruiting USA 0
NCT02025010 Phase II Abiraterone Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates. Active, not recruiting USA 0
NCT02034552 Phase II Prednisone Radium Ra 223 dichloride Enzalutamide Abiraterone A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) Completed USA 0
NCT02036918 Phase I Sipuleucel-T Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer Completed USA 0
NCT02043678 Phase III Prednisone Abiraterone Radium Ra 223 dichloride Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 9
NCT02057939 Phase II Enzalutamide Leuprolide Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) Completed USA 0
NCT02058706 Phase II Goserelin Bicalutamide Enzalutamide Leuprolide LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer Completed USA 0
NCT02064036 Phase I Bicalutamide Goserelin Leuprolide Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate Completed USA 0
NCT02064582 Phase II Leuprolide Enzalutamide Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer Completed USA 0
NCT02090114 Phase II Testosterone Abiraterone Enzalutamide RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study) Completed USA 0
NCT02099864 Phase II Enzalutamide Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Active, not recruiting USA 0
NCT02106507 Phase I Apalutamide + Everolimus ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate Completed USA 0
NCT02111187 Phase I Sonidegib A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer Completed USA 0
NCT02123758 Phase I Abiraterone + Apalutamide + Prednisone A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | NLD | GBR | CAN 0
NCT02125084 Phase I Enzalutamide + Everolimus Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer Completed USA 0
NCT02125357 Phase II Enzalutamide Abiraterone Sequencing Abiraterone and Enzalutamide in mCRPC Completed CAN 0
NCT02146833 Phase II Selinexor Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma Terminated USA 0
NCT02176161 Phase II Metformin Metformin Prostate Cancer Adjuvant Trial Completed USA 0
NCT02182622 Phase I Docetaxel Sonidegib LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Withdrawn USA 0
NCT02194842 Phase III Enzalutamide Enzalutamide + Radium Ra 223 dichloride Phase III Radium 223 mCRPC-PEACE III (PEACE III) Active, not recruiting ITA | GBR | FRA | ESP | CAN | BEL 6
NCT02199197 Phase II Enzalutamide Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer Completed USA 0
NCT02200614 Phase III Darolutamide Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 26
NCT02203695 Phase II Enzalutamide Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Active, not recruiting USA 0
NCT02204072 Phase I Enzalutamide Xentuzumab BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) Completed USA | NLD | GBR | ESP 4
NCT02207504 Phase I Crizotinib + Enzalutamide Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Completed USA 0
NCT02213107 Phase II Dutasteride + Enzalutamide Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. Completed USA 0
NCT02215096 Phase I Enzalutamide GSK2636771 Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer Completed USA | GBR 0
NCT02215161 Phase II Selinexor Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide Terminated USA 0
NCT02217566 Phase II Abiraterone Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy Completed 1
NCT02217709 Phase II Phenelzine Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer Completed USA 0
NCT02254785 Phase II Abiraterone Enzalutamide Cabazitaxel Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer Unknown status CAN | AUS 0
NCT02256111 Phase II Enzalutamide EXTEND Exercise Trial Completed USA 0
NCT02257736 Phase III Abiraterone + Apalutamide Abiraterone An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Active, not recruiting USA | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT02262910 Phase I MOR209/ES414 Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer Completed USA | AUS 0
NCT02268175 Phase II Enzalutamide Abiraterone Prednisone Leuprolide Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate Completed USA 0
NCT02284971 Phase I Varlilumab Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04) Terminated USA 0
NCT02286921 Phase II Enzalutamide Testosterone Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance Completed USA 0
NCT02303327 Phase III Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients Recruiting CAN 0
NCT02319837 Phase III Leuprolide Enzalutamide Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | AUT | AUS 8
NCT02346253 Phase Ib/II Leuprolide Triptorelin Degarelix Bicalutamide Goserelin High-Dose Brachytherapy in Treating Patients With Prostate Cancer Active, not recruiting USA 0
NCT02349139 Phase Ib/II ASN001 Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer Terminated USA 0
NCT02353715 Phase I Abiraterone Enzalutamide Sipuleucel-T Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing Completed USA 0
NCT02376166 Phase I Metformin Metformin for Rising PSA Remote Trial Completed USA 0
NCT02379390 Phase II Prednisone Abiraterone Enzalutamide Cabazitaxel Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB) Terminated USA | CAN 0
NCT02381236 Phase II Mipsagargin G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer Completed USA 0
NCT02384382 Phase II Enzalutamide A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) Completed USA 0
NCT02396368 Phase I Tasquinimod Radium Ra 223 dichloride A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer Withdrawn USA 0
NCT02407054 Phase II Enzalutamide LY3023414 A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Completed USA 0
NCT02411786 Phase I pTVG-AR Sargramostim A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF Completed USA 0
NCT02415621 Phase I Abiraterone Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer Active, not recruiting USA 0
NCT02441517 FDA approved Enzalutamide A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide Terminated USA 0
NCT02446405 Phase III Enzalutamide Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer Active, not recruiting USA | NZL | GBR | CAN | AUS 1
NCT02446444 Phase III Enzalutamide Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer Active, not recruiting USA | NZL | GBR | ESP | BEL | AUT | AUS 2
NCT02463799 Phase II Radium Ra 223 dichloride Sipuleucel-T Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC Completed USA 0
NCT02472275 Phase I Leuprolide Pexidartinib Goserelin Degarelix PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer Completed USA 0
NCT02489318 Phase III Apalutamide A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN | AUS 15
NCT02491411 Phase I Enzalutamide Dexamethasone Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel Terminated USA 0
NCT02494713 Phase II Degarelix Estramustine Docetaxel Doxorubicin Ketoconazole Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer Terminated USA 0
NCT02497638 Phase II Atorvastatin + Metformin LIpitor and biGuanide to Androgen Delay Trial Withdrawn CAN 0
NCT02499835 Phase Ib/II Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Completed USA 0
NCT02500901 Phase I Niraparib Enzalutamide Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) Terminated USA 0
NCT02506114 Phase II PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Ipilimumab Ipilimumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer Terminated USA 0
NCT02508636 Phase II Enzalutamide + Leuprolide Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Terminated USA 0
NCT02532114 Phase I Enzalutamide Niclosamide Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer Completed USA 0
NCT02543255 Phase II Cabazitaxel Abiraterone + Leuprolide + Prednisone Pegfilgrastim Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) Completed CAN 0
NCT02560051 Phase II Degarelix Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer Terminated USA 0
NCT02578797 Phase I Apalutamide A JNJ-56021927 (ARN-509) QT/QTc Study Completed USA | NLD | GBR | CAN 1
NCT02582749 Phase II Bicalutamide + Radium Ra 223 dichloride Bicalutamide Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases Terminated USA 0
NCT02601014 Phase II Ipilimumab + Nivolumab Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 Completed USA 0
NCT02606123 Phase Ib/II EPI-506 Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer Terminated USA | CAN 0
NCT02625857 Phase I JNJ-64041809 Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer Completed USA 0
NCT02643667 Phase Ib/II Ibrutinib A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer Completed USA 0
NCT02655822 Phase I Atezolizumab + CPI-444 CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Completed USA | CAN | AUS 0
NCT02677896 Phase III Enzalutamide A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT02685267 Phase II Docetaxel + Enzalutamide + Prednisone Docetaxel + Prednisone Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza) Terminated USA 0
NCT02685397 Phase II Enzalutamide Triptorelin Goserelin Leuprolide Management of Castration-Resistant Prostate Cancer With Oligometastases Recruiting CAN 0
NCT02703623 Phase II Ipilimumab Abiraterone + Apalutamide + Prednisone Cabazitaxel + Carboplatin A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO) Active, not recruiting USA 0
NCT02716974 Phase I Bicalutamide + Docetaxel + Leuprolide A Study of Definitive Therapy to Treat Prostate Cancer Completed USA 0
NCT02721979 Phase II Apalutamide ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance Terminated USA 0
NCT02758132 Phase I Abiraterone + Denosumab + Enzalutamide + Prednisone Denosumab + Enzalutamide Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases Terminated USA 0
NCT02768363 Phase II AdV-tk + Valacyclovir Valacyclovir Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) Active, not recruiting USA 1
NCT02770391 Phase II Apalutamide + Leuprolide ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer Completed USA 0
NCT02772588 Phase II Abiraterone + Apalutamide + Leuprolide AASUR in High Risk Prostate Cancer Active, not recruiting USA 0
NCT02787005 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199) Completed 0
NCT02788773 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Active, not recruiting CAN 0
NCT02793219 Phase II Docetaxel + Sipuleucel-T Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer Withdrawn USA 0
NCT02793765 Phase II Docetaxel + Sipuleucel-T Docetaxel Followed by Provenge in Metastatic Prostate Cancer Withdrawn USA 0
NCT02799602 Phase III Darolutamide Darolutamide + Docetaxel ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT02799706 Phase III Flutamide Degarelix Bicalutamide Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (PEGASUS) Active, not recruiting ITA | GBR | FRA | ESP | DEU | BEL 2
NCT02799745 Phase II Enzalutamide A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) (ENACT) Completed USA | CAN 0
NCT02805894 Phase Ib/II NBTXR3 NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma Terminated USA 0
NCT02811809 Phase II Leuprolide Apalutamide + Leuprolide Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer Withdrawn USA 0
NCT02814669 Phase I Atezolizumab + Radium Ra 223 dichloride Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor Completed USA 0
NCT02849990 Phase II Abiraterone + Apalutamide + Degarelix + Indomethacin + Prednisone Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery Completed USA 0
NCT02861573 Phase I Dexamethasone + Docetaxel + Pembrolizumab + Prednisone Olaparib + Pembrolizumab Enzalutamide + Pembrolizumab Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 10
NCT02893917 Phase II Cediranib + Olaparib Olaparib Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Active, not recruiting USA 0
NCT02903160 Phase II Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) Completed USA 0
NCT02903368 Phase II Abiraterone + Leuprolide + Prednisone Abiraterone + Apalutamide + Leuprolide + Prednisone Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy Active, not recruiting USA 0
NCT02905318 Phase II Palbociclib Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting CAN 0
NCT02906605 Phase II Apalutamide Apalutamide + JNJ-64041809 A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer Withdrawn USA 0
NCT02913196 Phase I Abiraterone + Apalutamide + Docetaxel + Prednisone Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC Active, not recruiting USA 0
NCT02923180 Phase I MGA271 Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer Active, not recruiting USA 0
NCT02949284 Phase II Apalutamide Abiraterone + Apalutamide + Prednisone Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery Recruiting USA 0
NCT02952534 Phase II Rucaparib A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT02975934 Phase III Rucaparib Docetaxel Enzalutamide Abiraterone A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT02987829 Phase Ib/II TRC253 A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients Completed USA 0
NCT02991911 Phase I Enzalutamide + MEDI3726 MEDI3726 A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer Completed USA | GBR 1
NCT02995330 Phase I Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Tacrolimus + Testosterone cypionate Cyclophosphamide + Fludarabine Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer Terminated USA 0
NCT03007732 Phase II Pembrolizumab + SD-101 Pembrolizumab Pembrolizumab in Combination With Intratumoral SD-101 Therapy Active, not recruiting USA 0
NCT03009981 Phase III Abiraterone + Apalutamide + Degarelix + Prednisone Apalutamide + Degarelix Degarelix A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Active, not recruiting USA 0
NCT03012321 Phase II Abiraterone + Olaparib + Prednisone Abiraterone + Prednisone Olaparib Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Active, not recruiting USA 0
NCT03016312 Phase III Atezolizumab + Enzalutamide Enzalutamide IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 11
NCT03024216 Phase I Atezolizumab + Sipuleucel-T Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer Completed USA 0
NCT03030885 Phase I 131I-MIP-1095 Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Completed USA 0
NCT03042468 Phase I lutetium Lu 177 vipivotide tetraxetan Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC Active, not recruiting USA 0
NCT03043807 Phase II Bicalutamide + Docetaxel + Leuprolide A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy Completed USA 0
NCT03047135 Phase II Olaparib Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Active, not recruiting USA 0
NCT03061539 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature Active, not recruiting GBR 0
NCT03070886 Phase III Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Active, not recruiting USA | CAN 1
NCT03072238 Phase III Abiraterone Abiraterone + Ipatasertib Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 17
NCT03076203 Phase I Niraparib + Radium Ra 223 dichloride Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone Completed USA 0
NCT03080116 Phase II Degarelix Apalutamide + Degarelix Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy (ARNEO) Unknown status BEL 0
NCT03085095 Phase III Relugolix Leuprolide A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO) Completed USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT03093272 Phase II Leuprolide Prednisone Apalutamide + Docetaxel A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer Terminated USA 0
NCT03093428 Phase II Pembrolizumab + Radium Ra 223 dichloride Radium Ra 223 dichloride Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC Active, not recruiting USA 0
NCT03098836 Phase II Abiraterone + Apalutamide + Prednisone Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer Active, not recruiting USA 0
NCT03147196 Phase II Bicalutamide + Raloxifene Raloxifene Bicalutamide Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Withdrawn 0
NCT03148795 Phase II Talazoparib A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 4
NCT03150056 Phase I Abiraterone + Molibresib Enzalutamide + Molibresib Prednisone Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer Terminated USA | GBR | ESP | AUS 0
NCT03177187 Phase Ib/II AZD5069 + Enzalutamide Combination Study of AZD5069 and Enzalutamide. (ACE) Terminated GBR 1
NCT03177460 Phase I Daratumumab Edicotinib Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer Completed USA 0
NCT03204812 Phase II Durvalumab + Tremelimumab Tremelimumab + Durvalumab Chemotherapy Naive CRPC Completed USA 0
NCT03248570 Phase II Pembrolizumab Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Completed USA 0
NCT03262103 Phase I Poly ICLC Neoadjuvant Hiltonol (PolyICLC) for Prostate Cancer Completed USA 0
NCT03276572 Phase I 225Ac-J591 Phase I Trial of 225Ac-J591 in Patients With mCRPC Completed USA 0
NCT03279250 Phase II Goserelin Triptorelin Abiraterone + Apalutamide + Prednisone Leuprolide Apalutamide Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence Completed USA 0
NCT03298087 Phase II Abiraterone + Apalutamide + Leuprolide Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer Completed USA 0
NCT03300505 Phase Ib/II AZD5312 + Enzalutamide ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer Terminated USA 0
NCT03317392 Phase Ib/II Olaparib Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone Suspended USA 0
NCT03338790 Phase II Enzalutamide + Nivolumab Nivolumab + Rucaparib Docetaxel + Nivolumab An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA | FRA | ESP | DEU | CAN | AUS 5
NCT03360721 Phase II Abiraterone + Apalutamide + Prednisone Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer Active, not recruiting USA 0
NCT03361735 Phase II Leuprolide + Radium Ra 223 dichloride Goserelin + Radium Ra 223 dichloride Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Active, not recruiting USA 0
NCT03365791 Phase II Ieramilimab Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03371719 Phase II Apalutamide Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer Active, not recruiting USA | CAN 0
NCT03385655 Phase II Savolitinib Darolutamide Adavosertib Prostate Cancer Biomarker Enrichment and Treatment Selection Active, not recruiting CAN 0
NCT03395197 Phase III Talazoparib Talazoparib + NHT vs. NHT Monotherapy in DDR+ mCRPC (TALAPRO-2) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 16
NCT03406858 Phase II Pembrolizumab Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Completed USA 0
NCT03412396 Phase II Apalutamide Single Arm Study of 6-Months Neoadjuvant ARN-509 Prior to Radical Prostatectomy Active, not recruiting USA 0
NCT03413995 Phase II Rucaparib Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) Active, not recruiting USA 0
NCT03414034 Phase II Abiraterone + Onvansertib + Prednisone PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer Completed USA 0
NCT03419234 Phase II Abiraterone + Prednisone Abiraterone + Cabazitaxel + Prednisone Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel Active, not recruiting USA 1
NCT03431350 Phase Ib/II Cetrelimab + Niraparib A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | ITA | GBR | ESP | CAN | BEL 1
NCT03432897 Phase II Olaparib BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes (337) Terminated USA 0
NCT03436654 Phase II Abiraterone + Apalutamide + Prednisone A Study of Hormonal Therapy and Apalutamide With or Without Abiraterone Acetate and Prednisone in Newly Diagnosed Prostate Cancers Active, not recruiting USA 0
NCT03437941 Phase Ib/II CORT125281 + Enzalutamide Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC Completed USA | GBR 0
NCT03442556 Phase II Carboplatin + Docetaxel + Rucaparib Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Active, not recruiting USA 0
NCT03456804 Phase II CEP-11981 ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer Completed USA 0
NCT03458247 Phase II Abiraterone Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer (OPTIMABI) Completed FRA 0
NCT03465345 Phase I Metformin + OPC Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Withdrawn USA 0
NCT03480646 Phase Ib/II Enzalutamide Abiraterone + CPI-1205 + Prednisone CPI-1205 + Enzalutamide ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Unknown status USA 0
NCT03503344 Phase II Apalutamide Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR) Active, not recruiting USA 0
NCT03506997 Phase II Pembrolizumab Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1) Recruiting GBR 0
NCT03511196 Phase I Abiraterone + Prednisone Leuprolide Goserelin Triptorelin Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Active, not recruiting USA 0
NCT03516812 Phase II Olaparib + Testosterone Enanthate Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer Completed USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03532217 Phase I Ipilimumab + Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer Completed USA 0
NCT03533946 Phase II Rucaparib Rucaparib in Nonmetastatic prOstAte With BRCAness (ROAR) Terminated USA 0
NCT03541928 Phase II Bicalutamide + HSV-Tk + Leuprolide + Valacyclovir Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery Unknown status USA 0
NCT03545165 Phase Ib/II 177Lu-J591 + lutetium Lu 177 vipivotide tetraxetan 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC Terminated USA 0
NCT03551782 Phase I Apalutamide + Cetrelimab A Study of JNJ-63723283, a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer Completed USA | NLD | ITA | ESP | CAN | BEL 1
NCT03554317 Phase II Nivolumab + Testosterone cypionate COMbination of Bipolar Androgen Therapy and Nivolumab Completed USA 0
NCT03556904 Phase II Abiraterone + Docetaxel + Enzalutamide FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) Completed USA 0
NCT03565835 Phase II Abiraterone + Prednisone Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer Active, not recruiting USA 0
NCT03570476 Phase II Olaparib Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer Terminated USA 0
NCT03570619 Phase II Ipilimumab + Nivolumab Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) Active, not recruiting USA 0
NCT03572387 Phase II Azacitidine + Leuprolide + Tretinoin A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment Completed USA 0
NCT03577028 Phase I HPN424 Study of HPN424 in Patients With Advanced Prostate Cancer Terminated USA | GBR 0
NCT03579654 Phase II Proscavax Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance Unknown status USA 0
NCT03600350 Phase II Nivolumab + pTVG-HP plasmid DNA vaccine + Sargramostim pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer Active, not recruiting USA 0
NCT03637543 Phase II Nivolumab Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Active, not recruiting USA 0
NCT03649841 Phase II Abiraterone + Prednisone Abiraterone + Prednisone + Radiotherapy Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate Cancer Terminated USA 0
NCT03678025 Phase III Docetaxel Nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Recruiting USA 4
NCT03686683 Phase III Sipuleucel-T Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (ProVent) Active, not recruiting USA 0
NCT03690141 Phase II Tomivosertib A Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC) Completed USA 0
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed USA | CAN | AUS 0
NCT03706365 Phase II Abemaciclib + Abiraterone + Prednisone Abiraterone + Prednisone A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Active, not recruiting USA | NLD | FRA | ESP | DEU | AUS 5
NCT03712930 Phase II Pamiparib Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency Terminated USA | ESP | AUS 1
NCT03724747 Phase I BAY 2315497 Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer Active, not recruiting USA | GBR 1
NCT03725761 Phase II Sacituzumab govitecan-hziy IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy Active, not recruiting USA 0
NCT03732820 Phase III Abiraterone Abiraterone + Olaparib Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT03734653 Phase I Enzalutamide + Testosterone Testosterone Therapy in Castration Resistant Prostate Cancer Active, not recruiting USA 0
NCT03748641 Phase III Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 19
NCT03753243 Phase II Enzalutamide + Pembrolizumab Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer Unknown status USA 0
NCT03767244 Phase III Apalutamide Abiraterone + Apalutamide Prednisone A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT03770455 Phase II Avelumab + Enzalutamide Abiraterone + Avelumab Phase II Trial of Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC Terminated USA 0
NCT03787680 Phase II Ceralasertib + Olaparib Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) Active, not recruiting USA 0
NCT03805594 Phase I lutetium Lu 177 vipivotide tetraxetan + Pembrolizumab 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA 0
NCT03809000 Phase II Goserelin Bicalutamide Enzalutamide Leuprolide A Trial to See What the Results Are for Radiation Therapy and Hormone Therapy vs Radiation Therapy With Enhanced Hormone Therapy With Enzalutamide for Patients With PSA Recurrence After Surgery (STEEL) Active, not recruiting USA | CAN 0
NCT03821246 Phase II Atezolizumab + Emactuzumab Atezolizumab Atezolizumab + Enzalutamide Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before Radical Prostatectomy Recruiting USA 0
NCT03821792 Phase II Abiraterone + Apalutamide + Prednisone Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer Active, not recruiting USA 0
NCT03827473 Phase II Abiraterone + Prednisone Docetaxel Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC) Terminated USA 0
NCT03829930 Phase I Entinostat + Enzalutamide Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer Terminated USA 0
NCT03833921 Phase II Abiraterone + Prednisone Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (APRE) Recruiting USA 0
NCT03834493 Phase III Enzalutamide + Pembrolizumab Enzalutamide Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 17
NCT03834506 Phase III Docetaxel + Prednisone Dexamethasone + Docetaxel + Pembrolizumab + Prednisone Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 11
NCT03834519 Phase III Abiraterone + Prednisone Enzalutamide Olaparib + Pembrolizumab Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010) Completed USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 9
NCT03837353 Phase Ib/II DKN-01 DKN-01 + Docetaxel A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 Terminated USA 0
NCT03840200 Phase Ib/II Ipatasertib + Rucaparib A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Completed USA | ITA | ESP | AUS 1
NCT03861403 Phase Ib/II Avelumab + Cyclophosphamide + TRX518 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Terminated USA 0
NCT03874884 Phase I lutetium Lu 177 vipivotide tetraxetan + Olaparib 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (LuPARP) Recruiting AUS 0
NCT03886493 Phase II Dupilumab Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer Terminated USA 0
NCT03888612 Phase I ARV-110 A Phase 1 Clinical Trial of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer. (mCRPC) Active, not recruiting USA 0
NCT03899077 Phase II Triptorelin Goserelin Degarelix Leuprolide Apalutamide Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (SAVE) Recruiting BEL 0
NCT03899987 Phase II Aspirin + Rintatolimod Aspirin + Interferon alpha-2b + Rintatolimod Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Suspended USA 0
NCT03902951 Phase II Abiraterone + Apalutamide + Leuprolide Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Active, not recruiting USA 0
NCT03903835 Phase III Docetaxel Cabazitaxel Carboplatin Abiraterone Enzalutamide ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (ProBio) Recruiting BEL 3
NCT03926013 Phase I JNJ-63898081 A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors Completed USA | CAN 0
NCT03939689 Phase II Enzalutamide 131I-MIP-1095 + Enzalutamide Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW) Active, not recruiting USA | CAN 0
NCT03964337 Phase II Cabozantinib Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC) Terminated USA 0
NCT03972657 Phase Ib/II Cemiplimab + REGN5678 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Recruiting USA 0
NCT03999515 Phase II Enzalutamide + Erdafitinib Abiraterone + Erdafitinib Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Terminated USA 0
NCT04015622 Phase II Docetaxel Enzalutamide PROTRACT (PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA) STUDY (PROTRACT) Recruiting CAN 0
NCT04019327 Phase Ib/II Talazoparib + Temozolomide A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Active, not recruiting USA 0
NCT04025372 Phase II Bicalutamide Darolutamide INTREPId (INTermediate Risk Erection PreservatIon Trial) Recruiting USA 0
NCT04033328 Phase I Enzalutamide + ORIC-101 Study of ORIC-101 in Combination With Enzalutamide Terminated USA 0
NCT04033432 Phase II sEphB4-HSA sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Unknown status USA 0
NCT04037254 Phase II Niraparib Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer Suspended USA | CAN 0
NCT04060394 Phase Ib/II Afuresertib + LAE001 + Prednisone Afuresertib Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Active, not recruiting USA 1
NCT04070209 Phase II Darolutamide Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) Recruiting CAN 0
NCT04077021 Phase I CCW702 First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer Terminated USA 0
NCT04090528 Phase II Pembrolizumab + pTVG-AR + pTVG-HP plasmid DNA vaccine + Sargramostim Pembrolizumab + pTVG-HP plasmid DNA vaccine + Sargramostim pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer Recruiting USA 0
NCT04090775 Phase II Cyclophosphamide + Ipilimumab + Nivolumab A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma Completed USA 0
NCT04097002 Phase Ib/II ORCA-010 First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. Active, not recruiting CAN 0
NCT04100018 Phase III Docetaxel + Nivolumab + Prednisone Docetaxel + Prednisone A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT04104893 Phase II Pembrolizumab A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP) Recruiting USA 0
NCT04109729 Phase Ib/II Nivolumab + Radium Ra 223 dichloride Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (Rad2Nivo) Recruiting USA 0
NCT04116775 Phase II Enzalutamide + Pembrolizumab Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Recruiting USA 0
NCT04126070 Phase II Docetaxel + Nivolumab Leuprolide Goserelin Degarelix Nivolumab + Docetaxel + ADT in Metastatic Hormone Sensitive Prostate Cancer Active, not recruiting USA 0
NCT04134260 Phase III Abiraterone + Apalutamide + Prednisone Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer Recruiting USA 0
NCT04136353 Phase III Darolutamide Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP) Active, not recruiting USA | NZL | GBR | CAN | AUS 1
NCT04157088 Phase II Enzalutamide Darolutamide Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) (DaroAcT) Terminated USA 0
NCT04175431 Phase II Abiraterone + Prednisone Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Recruiting USA 0
NCT04176081 Phase II Darolutamide + Degarelix Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer (SChLAP/IDC) Not yet recruiting CAN 0
NCT04179396 Phase I Enzalutamide + Rucaparib Abiraterone + Rucaparib Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP) Completed USA 0
NCT04179864 Phase I Enzalutamide + Tazemetostat Abiraterone + Prednisone + Tazemetostat A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | ESP | BEL 0
NCT04181203 Phase III Gonadorelin + Radiotherapy Apalutamide + Gonadorelin + Radiotherapy Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (CARLHA-2) Recruiting FRA 0
NCT04191096 Phase III Enzalutamide + Pembrolizumab Enzalutamide Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 18
NCT04194554 Phase Ib/II Abiraterone + Leuprolide + Niraparib + Prednisone A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (ASCLEPIuS) Recruiting USA 0
NCT04207255 Phase II ABC294640 + Enzalutamide ABC294640 + Abiraterone Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Active, not recruiting USA 0
NCT04237584 Phase III Darolutamide Darolutamide + Radium Ra 223 dichloride Enzalutamide Enzalutamide + Radium Ra 223 dichloride A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE) Terminated USA 0
NCT04262154 Phase II Abiraterone + Atezolizumab + Leuprolide + Prednisone Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer Active, not recruiting USA 0
NCT04272645 Phase II Abemaciclib + Atezolizumab Abemaciclib Atezolizumab Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer Withdrawn USA 0
NCT04288687 Phase II Niraparib A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects Active, not recruiting USA 0
NCT04291664 Phase I Abiraterone + Prednisone DST-2970 + Prednisone PK and Dose Escalation and Expansion Study of DST-2970 Active, not recruiting USA 0
NCT04295447 Phase II Apalutamide Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (ADAM) Recruiting DEU | AUT 0
NCT04296578 Phase I Abiraterone + Prednisone + Sodium Selenite Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone Withdrawn 0
NCT04298983 Phase II Abemaciclib Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer (RAD 1805) Active, not recruiting USA 0
NCT04301414 Phase I BMS-986218 + Degarelix Degarelix Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P) Active, not recruiting USA 0
NCT04302454 Phase III Leuprolide Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy (ADOPT) Recruiting NLD 0
NCT04319783 Phase II Darolutamide Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (DECREASE) Recruiting AUS 1
NCT04331717 Phase II Leuprolide Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer (BASH-PC) Withdrawn USA 0
NCT04332744 Phase II Enzalutamide + Talazoparib Enzalutamide Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) (ZZ-First) Active, not recruiting ESP 0
NCT04335682 Phase II Darolutamide Enzalutamide Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Recruiting USA 0
NCT04336943 Phase II Durvalumab + Olaparib Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load Active, not recruiting USA 0
NCT04343885 Phase II Docetaxel Docetaxel + lutetium Lu 177 vipivotide tetraxetan In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA) Active, not recruiting AUS 0
NCT04363164 Phase II Testosterone Enanthate Testosterone cypionate Enzalutamide Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Recruiting USA 0
NCT04382898 Phase Ib/II BNT112 + Cemiplimab BNT112 PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT) Terminated USA | GBR | DEU 1
NCT04393298 Phase Ib/II UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors Completed USA | GBR 0
NCT04397276 Phase I JNJ-70218902 A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors Active, not recruiting ESP | CAN 1
NCT04404140 Phase I Atezolizumab + Docetaxel + Ipatasertib A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). Terminated ITA | FRA | ESP 1
NCT04419402 Phase II Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Enzalutamide Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p) Active, not recruiting AUS 0
NCT04423211 Phase III Apalutamide + Leuprolide Apalutamide + Goserelin Leuprolide Goserelin Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging Recruiting USA 0
NCT04428203 Phase I Cannabidiol Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer Completed USA 0
NCT04428788 Phase I CC-94676 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT04430192 Phase Ib/II lutetium Lu 177 vipivotide tetraxetan Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy (LuTectomy) Active, not recruiting AUS 0
NCT04443062 Phase II lutetium Lu 177 vipivotide tetraxetan Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer (Bullseye) Recruiting NLD 1
NCT04446117 Phase III Enzalutamide Atezolizumab + Cabozantinib Abiraterone + Prednisone Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT04455750 Phase III Enzalutamide Goserelin + Leuprolide Enzalutamide + Rucaparib Degarelix A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR) Active, not recruiting USA 0
NCT04458311 Phase Ib/II Abiraterone + Tildrakizumab Abiraterone Acetate in Combination With Tildrakizumab (ACTIon) Terminated GBR 1
NCT04471974 Phase II Enzalutamide + Pembrolizumab + ZEN-3694 ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT04493853 Phase III Abiraterone + Capivasertib Abiraterone Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281) Active, not recruiting USA | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 22
NCT04495179 Phase II AZD4635 + Durvalumab AZD4635 + Cabazitaxel + Durvalumab A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (AARDVARC) Completed USA | FRA | ESP | BEL 1
NCT04497844 Phase III Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 22
NCT04506567 Phase Ib/II 225Ac-J591 Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC Recruiting USA 0
NCT04513717 Phase III Bicalutamide + Buserelin Buserelin + Flutamide Abiraterone + Apalutamide + Degarelix + Prednisone Abiraterone + Apalutamide + Buserelin + Prednisone Flutamide + Triptorelin Degarelix + Flutamide Abiraterone + Apalutamide + Leuprolide + Prednisone Flutamide + Leuprolide Flutamide + Goserelin Abiraterone + Apalutamide + Histrelin acetate + Prednisone Bicalutamide + Triptorelin Bicalutamide + Goserelin Flutamide + Histrelin acetate Bicalutamide + Degarelix Abiraterone + Apalutamide + Goserelin + Prednisone Abiraterone + Apalutamide + Prednisone + Triptorelin Bicalutamide + Leuprolide Bicalutamide + Histrelin acetate Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Recruiting USA | CAN 0
NCT04523207 Phase II Apalutamide A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases Completed USA 0
NCT04530552 Phase II Apalutamide Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Recruiting USA 0
NCT04536805 Phase Ib/II Metformin Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin (REPAIRGETUGP16) Recruiting FRA 0
NCT04556617 Phase Ib/II Olaparib + PLX2853 Abiraterone + PLX2853 + Prednisone PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Terminated USA | GBR 0
NCT04557059 Phase III Apalutamide + Triptorelin Triptorelin Apalutamide + Goserelin Apalutamide + Leuprolide Leuprolide Goserelin A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM) Recruiting USA | ITA | ESP | DEU | BEL | AUT | AUS 14
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) Recruiting USA | GBR 6
NCT04569461 Phase II Pembrolizumab Trimodality Approach to Localized Prostate Cancer: Pembrolizumab, ADT, and SBRT Followed by Prostatectomy (TALON) Not yet recruiting USA 0
NCT04576871 Phase I 225Ac-J591 Re-treatment 225Ac-J591 for mCRPC Recruiting USA 0
NCT04577833 Phase I Abiraterone + Niraparib + Prednisone A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer Active, not recruiting USA | NLD | GBR | FRA | ESP | BEL 5
NCT04628988 Phase I Abiraterone + CC-90011 + Prednisone A Study of CC-90011 and Comparators in Participants With Prostate Cancer Completed USA 0
NCT04631601 Phase I AMG 160 + AMG 404 AMG 160 + Enzalutamide Abiraterone + AMG 160 AMG 404 Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) Terminated USA | GBR | ESP | AUS 2
NCT04635059 Phase II Pacritinib Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer (BLAST) Active, not recruiting USA 0
NCT04641078 Phase II Darolutamide Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer (DART) Recruiting BEL 0
NCT04647526 Phase III Abiraterone + Dexamethasone Abiraterone + Prednisone Enzalutamide PNT2002 Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) Active, not recruiting USA | NLD | GBR | FRA | CAN 1
NCT04655365 Phase II Enzalutamide Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. (PROSTEP-002) Recruiting CAN 0
NCT04662580 Phase I ARX517 ARX517 in Subjects With Advanced Solid Tumor (ARX517) Recruiting USA 0
NCT04666129 Phase I Abiraterone + Prednisone + Relugolix Study of Relugolix in Men With High-Risk Metastatic Castration-Sensitive Prostate Cancer or Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA 0
NCT04689828 Phase III lutetium Lu 177 vipivotide tetraxetan 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer Active, not recruiting USA | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUT 5
NCT04691804 Phase III Abiraterone + Fluzoparib + Prednisone Abiraterone + Prednisone A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting USA | GBR | FRA | ESP | BEL | AUS 7
NCT04709276 Phase II Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) Recruiting USA 0
NCT04717154 Phase II Ipilimumab + Nivolumab Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE) Active, not recruiting NLD 0
NCT04720157 Phase III lutetium Lu 177 vipivotide tetraxetan An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition) Active, not recruiting USA | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUT 10
NCT04726332 Phase I Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) Terminated USA 0
NCT04734730 Phase II Abiraterone + Bicalutamide + Leuprolide + Prednisone + Talazoparib Abiraterone + Goserelin + Prednisone + Talazoparib Abiraterone + Degarelix + Prednisone + Talazoparib Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Recruiting USA 0
NCT04736199 Phase III Darolutamide Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE) Active, not recruiting NZL | ESP | CAN | AUS 11
NCT04740034 Phase I AMG 340 A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma Active, not recruiting USA 0
NCT04748042 Phase II Abiraterone + Olaparib + Prednisone Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) Recruiting USA 0
NCT04751929 Phase II Abemaciclib + Atezolizumab Atezolizumab Abemaciclib Abemaciclib With or Without Atezolizumab for mCRPC Active, not recruiting USA 0
NCT04754191 Phase II Enfortumab vedotin-ejfv Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer (ENCORE) Recruiting USA 0
NCT04754425 Phase II Erdafitinib Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Active, not recruiting USA 0
NCT04781374 Phase II Neratinib Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer Withdrawn USA 0
NCT04812366 Phase II Abiraterone + Apalutamide + Prednisone Apalutamide Abiraterone + Prednisone Apalutamide + Atezolizumab Abiraterone + Docetaxel + Prednisone Abiraterone + Niraparib + Prednisone Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS) Recruiting USA | CAN 0
NCT04821622 Phase III Enzalutamide Enzalutamide + Talazoparib Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT04824937 Phase II Talazoparib + Telaglenastat Telaglenastat + Talazoparib In Prostate Cancer Unknown status USA 0
NCT04844749 Phase III Abiraterone Enzalutamide VERU-111 Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERU-111) Terminated USA 0
NCT04886986 Phase Ib/II 225Ac-J591 + PNT2002 225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC Suspended USA 0
NCT04887506 Phase III Abiraterone + Prednisone Prednisone + TAVT-45 TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Completed USA | GBR | FRA | ESP 4
NCT04898634 Phase I JNJ-78278343 A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Recruiting USA | NLD | FRA | ESP 0
NCT04916613 Phase III Darolutamide ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Unfit) Recruiting FRA | ESP | BEL 1
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04925648 Phase II Darolutamide + Dasatinib Dasatinib Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (PICASSO) Recruiting AUS 0
NCT04926181 Phase II Apalutamide + Cetrelimab Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Active, not recruiting USA 0
NCT04931979 Phase II Pembrolizumab SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy (Pembro-SRT) Recruiting DEU 0
NCT04946370 Phase Ib/II Pembrolizumab 225Ac-J591 + Pembrolizumab Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC Recruiting USA 0
NCT04951492 Phase II Olaparib Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma Terminated USA 0
NCT04989946 Phase Ib/II Degarelix Degarelix + Nivolumab + pTVG-AR Degarelix + pTVG-AR Androgen Deprivation, With or Without pTVG-AR, and With or Without Nivolumab, in Patients With Newly Diagnosed, High-Risk Prostate Cancer Recruiting USA 0
NCT05010200 Phase I CDX-301 + PGV 001 + Poly ICLC PGV 001 + Poly ICLC The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. (PGV-Prostate) Recruiting USA 0
NCT05011188 Phase Ib/II Enzalutamide + FOR46 FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer Recruiting USA 0
NCT05011383 Phase II Testosterone High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers (VA-BAT) Recruiting USA 0
NCT05019846 Phase III Bicalutamide + Triptorelin SRT Versus SRT+ADT in Prostate Cancer (SPA) Recruiting ITA 0
NCT05022849 Phase I JNJ-75229414 A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants Active, not recruiting USA 0
NCT05050084 Phase III Buserelin Relugolix Degarelix Goserelin Leuprolide Histrelin acetate Triptorelin Darolutamide + Goserelin Bicalutamide Darolutamide + Degarelix Darolutamide + Leuprolide Darolutamide + Triptorelin Buserelin + Darolutamide Darolutamide + Histrelin acetate Flutamide Darolutamide + Relugolix Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Recruiting USA | CAN 0
NCT05053152 Phase II Relugolix Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer (NRG PROMETHEAN) Recruiting USA | CAN 0
NCT05059236 Phase II Darolutamide A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (ARASEC) Active, not recruiting USA 0
NCT05075577 Phase Ib/II Enzalutamide + EPI-7386 Enzalutamide EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC Recruiting USA | CAN | AUS 0
NCT05077098 Phase I ADXS-504 Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer Recruiting USA 0
NCT05079698 Phase I lutetium Lu 177 vipivotide tetraxetan A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer Active, not recruiting USA 0
NCT05081193 Phase II Enzalutamide + Testosterone Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer Recruiting USA 0
NCT05100472 Phase II Bicalutamide + Leuprolide A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer Active, not recruiting USA 0
NCT05110495 Phase I Xentuzumab Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy (WINGMEN) Active, not recruiting GBR 0
NCT05116475 Phase III Darolutamide Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases (ALADDIN) Recruiting FRA 0
NCT05124795 Phase I IMU-935 IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer Terminated GBR 0
NCT05125016 Phase Ib/II REGN4336 Cemiplimab + REGN4336 REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT05150236 Phase II Ipilimumab + lutetium Lu 177 vipivotide tetraxetan + Nivolumab lutetium Lu 177 vipivotide tetraxetan Nivolumab 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION) (EVOLUTION) Active, not recruiting AUS 0
NCT05156905 Phase II Cirmtuzumab + Docetaxel Phase 2 Trial of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer Recruiting USA 0
NCT05168618 Phase II Atezolizumab + Cabozantinib Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial Recruiting USA 0
NCT05176483 Phase I Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 3
NCT05177042 Phase I Abiraterone + ARV-110 Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Active, not recruiting USA | GBR | FRA | CAN 0
NCT05204927 Phase III Abiraterone + Enzalutamide lutetium Lu 177 vipivotide tetraxetan Abiraterone + Prednisone Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | ITA | FRA | ESP 0
NCT05219500 Phase II FPI-2265 Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST) Recruiting USA 0
NCT05230251 Phase II PNT2002 Radioligand fOr locAl raDiorecurrent proStaTe cancER (ROADSTER) Active, not recruiting CAN 0
NCT05252364 Phase I HP518 A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer Completed AUS 0
NCT05288166 Phase III Abiraterone + Prednisone Abemaciclib + Abiraterone + Prednisone A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 14
NCT05295927 Phase I Apalutamide + EPI-7386 Abiraterone + EPI-7386 + Prednisone A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Terminated USA | CAN 0
NCT05340374 Phase Ib/II Cabazitaxel + lutetium Lu 177 vipivotide tetraxetan Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (LuCAB) Recruiting AUS 0
NCT05348577 Phase III Capivasertib + Docetaxel Docetaxel Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello-280) Recruiting USA | NLD | GBR | FRA | ESP | CAN | BEL | AUS 14
NCT05383079 Phase Ib/II Lutetium-177 PSMA-I&T Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer: Phase I/II Study (AlphaBet) Recruiting AUS 0
NCT05393791 Phase II Abiraterone + Enzalutamide Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt) Recruiting NLD | AUS 0
NCT05404139 Phase II Enzalutamide Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) Recruiting CAN 0
NCT05413850 Phase Ib/II 177Lu-rhPSMA-10.1 Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection Recruiting USA | NLD 0
NCT05422911 Phase II Enzalutamide Abiraterone Apalutamide Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. Not yet recruiting USA 0
NCT05425862 Phase I CX-5461 + Talazoparib Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (REPAIR) Suspended AUS 0
NCT05441501 Phase I JNJ-80038114 A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer Completed USA | GBR 0
NCT05445609 Phase II Nivolumab + Vidutolimod Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Recruiting USA 0
NCT05496959 Phase II PNT2002 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (LUNAR) Active, not recruiting USA 0
NCT05498272 Phase II Leuprolide + Olaparib Goserelin + Olaparib Olaparib + Triptorelin Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune) Recruiting USA 0
NCT05502315 Phase II Cabozantinib + Nivolumab Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY) Recruiting USA 0
NCT05519449 Phase I JANX007 Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) Recruiting USA | AUS 0
NCT05526248 Phase II Enzalutamide Darolutamide A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide (ARAMON) Recruiting USA 0
NCT05551117 Phase II MGC018 A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer (Tamarack) Active, not recruiting USA | ITA | GBR | FRA | ESP | BEL | AUS 2
NCT05553639 Phase Ib/II HB-302/HB-301 HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT05563558 Phase II Cabazitaxel + Carboplatin + Pembrolizumab Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) (PEAPOD_FOS) Recruiting ESP 0
NCT05567770 Phase I 225Ac-J591 ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer (ACTION) Withdrawn 0
NCT05568550 Phase II Pembrolizumab Olaparib + Pembrolizumab Pembro With Radiation With or Without Olaparib Recruiting USA 0
NCT05585034 Phase I Pembrolizumab + XmAb808 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors Recruiting USA 0
NCT05588609 Phase II Enzalutamide + Zenocutuzumab Afatinib + Zenocutuzumab Abiraterone + Zenocutuzumab Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers Recruiting USA 0
NCT05593497 Phase II Abiraterone + Capivasertib A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (SNARE) Not yet recruiting USA 0
NCT05613894 Phase I Cabozantinib + lutetium Lu 177 vipivotide tetraxetan Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (CaboLu) Recruiting USA 0
NCT05617885 Phase Ib/II Abemaciclib + Darolutamide + Degarelix + Goserelin + Leuprolide Darolutamide + Degarelix + Goserelin + Leuprolide Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer Active, not recruiting USA 0
NCT05620914 Phase I Patritumab deruxtecan A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) Not yet recruiting USA 0
NCT05646550 Phase I CC-1 Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer (ProSperACC-1) Recruiting DEU 0
NCT05676203 Phase III Darolutamide + Docetaxel A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients (ARASAFE) Recruiting DEU 0
NCT05682443 Phase II lutetium Lu 177 vipivotide tetraxetan + ONC-392 lutetium Lu 177 vipivotide tetraxetan ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (PRESERVE-006) Recruiting USA 0
NCT05689021 Phase II Niraparib and abiraterone acetate + Prednisone CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Recruiting USA 0
NCT05691465 Phase II lutetium Lu 177 dotatate Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells Recruiting USA 0
NCT05700669 Phase Ib/II AsiDNA + Olaparib Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors Recruiting USA 0
NCT05719558 Phase I ASP1002 A Study of ASP1002 in Adults for Treatment of Solid Tumors Active, not recruiting USA 0
NCT05720130 Phase Ib/II 212Pb-ADVC001 Dose Escalation and Efficacy Study of 212Pb-ADVC001 in Patients With Metastatic Castration Resistant Prostate Cancer. Recruiting AUS 0
NCT05726292 Phase II Enzalutamide Enzalutamide + Relacorilant A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Recruiting USA 0
NCT05733351 Phase I Abiraterone + XmAb20717 Enzalutamide + XmAb20717 Abiraterone + Docetaxel + XmAb20717 Vudalimab in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer Recruiting USA 0
NCT05766371 Phase II lutetium Lu 177 vipivotide tetraxetan + Pembrolizumab Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer Recruiting USA 0
NCT05794906 Phase III Darolutamide A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Nonmetastatic Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP) Recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT05800665 Phase I RO7656594 A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer Recruiting USA | AUS 1
NCT05818683 Phase I Cetrelimab + JNJ-78278343 A Study of JNJ-78278343 in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer Recruiting USA | AUS 0
NCT05826509 Phase II Darolutamide SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer (SUGAR) Recruiting FRA 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05848011 Phase II Docetaxel + MGD019 + Prednisone Docetaxel + Prednisone A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Recruiting USA | GBR | FRA | ESP | BEL | AUS 4
NCT05873192 Phase II Degarelix + Enzalutamide + Talazoparib Enzalutamide + Leuprolide + Talazoparib Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer Not yet recruiting USA 0
NCT05884398 Phase III Apalutamide A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS) Recruiting USA | FRA | DEU | CAN | AUS 4
NCT05915442 Phase II AB680 + Etrumadenant + Zimberelimab Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer (SBRT-AMICO) Recruiting USA 0
NCT05917470 Phase Ib/II ONCT-534 A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Recruiting USA | GBR 0
NCT05960578 Phase II Apalutamide + golimumab Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Recruiting USA 0
NCT05988918 Phase II CEP-11981 Multicenter Trial of ESK981 in Patients With Select Solid Tumors Recruiting USA 0
NCT05997615 Phase Ib/II AMX-500 Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Recruiting GBR | ESP | AUS 0
NCT05999968 Phase I Abemaciclib + Darolutamide Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Active, not recruiting USA | ESP | DEU 0
NCT06014255 Phase II MGA271 Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer (HEAT) Recruiting USA 0
NCT06029998 Phase II Bortezomib Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion (BORXPTEN) Recruiting USA 0
NCT06033001 Expanded access PNT2002 Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Available USA 0
NCT06039371 Phase II Etoposide + Testosterone cypionate Carboplatin + Testosterone cypionate Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Recruiting USA 0
NCT06052306 Phase I BAY3546828 BAY2315493 A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting NLD | GBR 1
NCT06056791 Phase Ib/II INKmune Study of INKmune in Patients With mCRPC (CaRe Prostate) (CaRe) Recruiting USA 0
NCT06059118 Phase II Eflornithine Eflornithine + Testosterone cypionate Enzalutamide Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT06067269 Phase II Apalutamide Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE) Recruiting USA 0
NCT06067841 Phase I BMS-986460 A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer Recruiting USA 0
NCT06084338 Phase II lutetium Lu 177 vipivotide tetraxetan + Testosterone lutetium Lu 177 vipivotide tetraxetan Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc Recruiting USA 0
NCT06085664 Phase Ib/II REGN5678 A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy Recruiting USA 0
NCT06095089 Phase I JNJ-78278343 + JNJ-87189401 A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer Recruiting USA | FRA 0
NCT06100705 Phase II Sipuleucel-T + Testosterone cypionate Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC Recruiting USA 0
NCT06105918 Phase I 177Lu-rhPSMA-10.1 Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer Recruiting USA 0
NCT06111313 Phase II Relugolix The University of Miami Adapt (UAdapt) Trial Not yet recruiting USA 0
NCT06120491 Phase III AZD5305 + Enzalutamide Abiraterone + AZD5305 AZD5305 + Darolutamide Darolutamide Enzalutamide Abiraterone AZD5305 vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT06130995 Phase I Enzalutamide + Relugolix Relugolix + Enzalutamide Study in High-Risk Prostate Cancer Not yet recruiting USA 0
NCT06136624 Phase III Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide Abiraterone Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 18
NCT06136650 Phase III Abiraterone + Prednisone Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) Recruiting USA | ITA | GBR | FRA | ESP | DEU | AUS 19
NCT06145633 Phase II lutetium Lu 177 vipivotide tetraxetan Vorinostat Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer Not yet recruiting USA 0
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT06173362 Phase II Darolutamide Abiraterone + Prednisone Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer Recruiting USA 0
NCT06190899 Phase Ib/II Darolutamide + Gedatolisib Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Recruiting USA | GBR | FRA | ESP 0
NCT06212583 Phase II Abiraterone + Niraparib High-Risk Metachronous Oligometastatic Prostate Cancer Trial (KNIGHTS) Recruiting USA 0
NCT06236139 Phase Ib/II Cyclophosphamide + Fludarabine Anti-STEAP1 CAR-T cells + Enzalutamide Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Not yet recruiting USA 0
NCT06257693 Phase I Enzalutamide Enzalutamide Implants (Enolen) in Patients With Prostate Cancer Not yet recruiting USA 0
NCT06267729 Phase Ib/II AZD0754 Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO) Recruiting USA | AUS 0
NCT06303713 Phase I Carboplatin + lutetium Lu 177 vipivotide tetraxetan LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer Not yet recruiting USA 0
NCT06312670 Phase II Enzalutamide + EPI-7386 Combining EPI-7386 w/ Enzalutamide & Androgen Deprivation Therapy for Newly Diagnosed Prostate Cancer Not yet recruiting USA 0
NCT06318273 Phase I ABBV-969 A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 1
NCT06329830 Phase Ib/II lutetium Lu 177 vipivotide tetraxetan + Niraparib and abiraterone acetate + Prednisone 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR) Not yet recruiting USA 0
NCT06388369 Phase Ib/II lutetium Lu 177 vipivotide tetraxetan Ipilimumab + lutetium Lu 177 vipivotide tetraxetan Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer (NEPI) Not yet recruiting DEU 0
NCT06402331 Phase II FPI-2265 FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak) Recruiting USA 0